into several main groups including: metabolic disorders, neuromuscular disorders, blood disorders, cardiovascular and respiratory disorders, autoimmune diseases, skin diseases and rare neoplasms (4) .
There are challenges with the management of rare diseases. These challenges include the geographical dispersion of patients and rare diseases specialists, limited number of specialists, the lack of consistency and integrity of studies, limited access to credible sources, and limited information and knowledge (4, 6) . Development of an integrated information system for rare diseases, for example, at a national level could help to eliminate part of the challenges experienced due to information restrictions (7, 8) .This issue was emphasized in the main recommendations of the European Union Council on rare diseases in 2013 (9, 10) . A well-developed information system for rare diseases requires addressing the principles of information systems architecture in practice (7) . A key aspect of information systems architecture is data architecture (11, 12) , consisted of models, standards and methods that depict various data types and the methods for data collection, storage, processing, retrieval, and sharing (12, 13) . In relation to information system for rare diseases, the data architecture provides an overview of the data that should be available in the information system and provides a concrete infrastructure for data flow and sharing (14) .
The main objective of this review is to identify the data architecture of rare diseases information system in the published studies addressing this system in terms of data content and data interactions. By presenting the current literature in rare diseases information systems, it is hoped that this review could contribute to a better understanding of the system data architecture.
Data Collection
The search for relevant English language articles, based on keywords in title, abstract, Mesh and Emtree terms, was done in Pubmed and Embase (from 1980 to June 2017), Scopus, Science Direct and Cochran (from 1980 to July 2017). Figure 1 shows the search strategy for identifying the relevant articles. The first part (Part A) included terms used for rare diseases. In the second part (Part B), the keywords related to the data management tools were used. The third part (Part C) contained terms in relation to studies on information system data architecture. The results of these three parts were combined using the Boolean operator "and". Searching was supplemented with checking the bibliographies of identified articles.
Three reviewers examined independently the title and abstracts of the identified articles. Articles were selected if they address data architecture of information systems with a focus on rare diseases, and if at least one of their objectives dealt with design, implementation, and development of rare diseases information systems, and if they studied the network, databases, and registries of these diseases at the regional, national or international level. All studies that merely focused on the design and evaluation of specific software, or data architecture with no focus on rare diseases were excluded. The process and the results of the literature search are illustrated in Figure 2 .
Data Analysis
Searching the online databases resulted in 3520 articles from Pubmed, Embase, Scopus, Science Direct, and Cochrane after removing duplicates. Initial screening of titles and abstracts resulted in 145 articles, of which 113 articles were excluded because they did not address data architecture in relation to rare diseases. Three further articles were identified through checking the bibliographies, leading to a total of 35 articles for full text review (Figure 2) .
Considering the geographical origins of the reviewed studies, 20 studies conducted in Europe (8) (9) (10) 12, (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , 7 studies in USA (31-37), 4 studies in Australia (38) (39) (40) (41) and 4 studies were performed in Asia (42) (43) (44) (45) .
Some of these organizations may belong to more than one group. The most important organizations producing rare disease data are clinics, reference centers for rare diseases, hospitals, research consortia, universities and academic centers (21, 31, 35) .
Organizations considered as data-user included research centers, specialized scientific associations, physicians, universities, health managers and policy makers, insurance companies, pharmaceutical companies and medical equipment providers (18, 21, 27, 31, 35, 38) . The third group, i.e., coordinating and governing bodies, are in charge of implementing laws and standards and overseeing activities related to data generation, processing, storage and use to ensure that data are handled in safe and secure manner (18) . The Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH) in USA (31, 35) , and the NHS National Institute of Health Research (NIHR) in England (18) are examples of governing organizations.
Data Sources and Databases
The most significant data sources are the general and
The main findings from the analysis of the studies are categorized in the following six groups, including organization in charge of rare diseases data generation, adoption and governance (10, 15, 17, 18, (20) (21) (22) (23) (24) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (43) (44) (45) ; data sources (8) (9) (10) (15) (16) (17) (18) (20) (21) (22) (23) (24) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) 39, 40, 43, 45) , datasets, (8) (9) (10) (15) (16) (17) 19, (21) (22) (23) (24) 26, (28) (29) (30) (31) (32) 34, (37) (38) (39) (40) (41) data standards (8, 9, 16, (19) (20) (21) (22) 24, 27, 29, 32, 36, 37, 43, 45) , data sharing (15) (16) (17) (18) (20) (21) (22) (27) (28) (29) 31, (33) (34) (35) 38, 40, (43) (44) (45) ) and data quality (10, (15) (16) (17) (18) (21) (22) (23) (24) (25) 27, 28, (30) (31) (32) 43, 45) .
Organizations involved in data generation, adoption, and governance
Identifying the organizations that generate, adopt, and govern data could help to lay the foundation for concrete data architecture of information system for rare diseases. According to the studies, organizations dealing with rare disease information systems could be categorized into three main groups: (i) data-producers (10, 17, 18, (20) (21) (22) (23) 28, 29, (31) (32) (33) 35, 36, (38) (39) (40) 44, 45) , (ii) data users (15, 17, 18, (21) (22) (23) (27) (28) (29) (31) (32) (33) (34) (35) (37) (38) (39) 41, (43) (44) (45) , and (iii) data coordinators and governors (10, 15, 17, 18, (20) (21) (22) (23) (24) (27) (28) (29) (30) (31) 33, (35) (36) (37) 45) . specialized rare diseases clinics and research centers, which are the most important producers of clinical and epidemiological data for these diseases. Furthermore, data can be captured from hospitals, research centers, bio-banks. In some systems, it is possible for patients or their relatives to enter data related to disease progress, the quality of their lives and other issues (15, 16, 31, 39) . A summary of the data sources is categorized in Table 1 .
Datasets and data elements
Twenty three studies addressed datasets and their related data elements. The datasets are categorized into three main groups: a common dataset for rare diseases, specific datasets, and complementary or extended dataset. Common dataset and its data elements were mentioned in 22 studies (8) (9) (10) (15) (16) (17) 19, (21) (22) (23) (24) 26, (28) (29) (30) (31) (32) (37) (38) (39) (40) (41) . This dataset includes data elements applied to a wide range of rare diseases, such as patients' demographic data, different types of rare diseases, centers delivering services to patients, medication history and medical records of patients, family history, prenatal and neonatal records ( Table 2) . Eight studies indicated the data elements required for a specific dataset (8, 10, 17, 19, 21, 26, 34, 39) . This dataset includes data specific to a particular rare disease and is only applied for the same disease. The dataset for Cystinosis, Nephronophytosis, Turner Syndrome and Neonatal Diabetes (21) are examples of this type of dataset. The extended dataset includes data elements that are not available in the two aforementioned groups, but they add to, and improve, the knowledge about rare diseases. This category includes high encouraged data such as the experiences of patients and care givers, and data from studies addressed a particular aspect and conducted on an ad hoc basis (8, 10, 15, 16, 24, 26) .
Data standards
Fifteen studies showed the application of terminologies, nomenclatures, and international classifications of diseases including ICD 10, Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT), and Logical Observation Identifiers Names and Codes (LOINC), as well as information exchange standards such as HL7 for data organization, developing datasets, and data sharing. The most commonly used standards are listed in Table 3 . Classification systems such as ICD 10, Online Mendelian Inheritance in Man (OMIM) and ORPHA-codes were the most used systems.
Data sharing
Nineteen studies indicated data sharing among different bodies. Data sharing among parties such as scientific and academic communities, clinics, and the national database of rare diseases was reported in 12 studies (15) (16) (17) 21, 22, (27) (28) (29) 31, (33) (34) (35) . Data exchange of central registry with the local databases or registries were indicated in 12 studies (20) (21) (22) (27) (28) (29) 31, 33, 38, 40, 43, 45) .
Data interactions among academies, research centers and clinics were reported in 10 studies (18, (20) (21) (22) 27, 31, 33, 35, 38, 44) . In addition, seven studies indicated data sharing of patients or their relatives with registries of rare diseases (17, 18, 29, 31, 33, 35, 40 ).
Data quality control
T h e n e c e s s i t y o f c o n t r o l l i n g t h e q u a l i t y o f data generated in the information systems was highlighted in 17 studies. In 14 studies, the data producers were in charge of data quality control (15) (16) (17) 21, 22, 24, 25, 27, 28, (30) (31) (32) 43, 45) ; and in 8 studies, data coordinators and governors took this responsibility (10, 15, 16, 18, 24, 27, 31, 45) . In some studies, bodies such as quality control committees or departments (10, 16, 23) and independent experts (10, 17, 25, 30, 43) were in charge of checking the quality of data. Table 4 demonstrates a summary of the main data quality control procedures together with criteria used in this respect. Ten studies referred to cross review checking as a routine for checking the quality of data through applying measures including accuracy, consistency, and completeness. Checking for duplications and missing data were among the other approaches for controlling data quality focusing mainly on the adequacy of data. Accuracy, as a data quality measure, was referred to in all of the studies that remarked the necessity of controlling data quality.
Discussion
Over the past two decades, there has been an increasing attention to rare diseases and managing these diseases (6) . France, the United Kingdom (UK), and the United States are viewed as pioneer countries in terms of legislation, setting standards, developing of a network infrastructure for rare diseases, and creating information systems for these diseases (6,10,18,21,27,29-31,35,37).
Organizations involved in data generation and governance
Different organizations are dealing with rare diseases data. Continued monitoring and financial support by coordinators and governors could help data producer organizations to generate data considering data quality requirements. Data producer organizations, in turn, could feed governor organizations by high quality data to set and update relevant policies. In addition, data user organizations, such as research and care centers could have improved performance when using high quality data.
One of the main issues with management of rare diseases data is collecting data by different organizations in parallel resulted in data redundancy and duplication of efforts. Organizations such as research centers, clinics and hospitals may have their own exclusive databases for data collection. Developed countries have design and implemented a national integrated information network for managing rare diseases data, in which governing organizations play a coordinating role to avoid duplication of data collection (31,32).
Data sources and datasets
As the findings showed, there are a variety of data sources for a rare disease information system. Developing a national rare disease information system with the capability of data sharing with different data sources has a key role to play in efficient data management (9, 46) .
Due to the diversity of data sources, it is very challenging to determine a certain dataset for rare diseases. Common and specific datasets are two main datasets for rare diseases, in which the association between the common and specific datasets could be depicted in the form of a flower known as the Petal model (17) . In this model, the common dataset constitutes the central core of the flower and the specific datasets of each rare disease make the petals and can be gradually added to the core part (17, 21) . In developed countries, work groups and specialized consortia are in charge of defining specific datasets for each of the rare diseases groups (8, 26, 35, 47) .
The findings indicated the diversity of rare diseases data and data sources causing difficulties with data management. This issue could be eliminated through developing an integrated information system and the application of data standards.
Data standards
The use of standards could improve data quality and the interoperability of systems (8) . In relation to the terminology and classification standards, these standards could be used to report the results of diagnostic tests (8, 21, 22) , classify the conditions and provided services for statistical analysis, and reimburse of the costs (20, 27, 29) . Since no standard for diagnostic codes is yet created for the classification of rare diseases, many countries have been using ICD-10. However, this disease classification lacks many of rare diseases and genetic disorders and does not fully support the detailed classification of these diseases (21, 22, 48) . To overcome this issue, there have been global efforts coordinated by the World Health Organization to develop classification codes for rare diseases (5, 48) . Currently, a greater compatibility with the majority of genetic rare diseases is anticipated in ICD 11. Therefore, it is highly recommended to use ICD 11 and the ORPHA-codes simultaneously, as a valid ontology for rare diseases, although the alignment of ORPHA codes with SNOMED-CT, ICD-10 and OMIM is still in progress and requires further development (5, 17, 48) . Some European countries such as France, use ORPHA codes rather than ICD-10 and SNOMED-CD (21, 22) , and this could be due the ORPHA codes being more specific and allowing better organization of rare diseases data.
Data sharing
With respect to data sharing, standards such as the HL7 support the exchange of data. This standard facilitates data sharing among different organizations, such as health and research centers, as well as policy making organizations (8, 31, 35) . As findings indicated, different types of data could be shared among different bodies (46) . Data sharing of health and research centers with the rare diseases registry is a main type of data interaction. Knowing that the most of bodies involved in data sharing are considered as both data producers and data users, their interactions with rare diseases registry is often two-dimensional, as they could send clinical and epidemiological data to the registry and receive information such as the relationship between phenotype and genotype characteristics of any rare disease (18, 27, 46) . Another important type of data sharing could be seen between a central database or registry and other databases or specialized registries. In this type of data sharing, the central registry acts as a hub and interacts with other registries (20, 43) .
Data quality control
The other key aspect of data architecture for rare diseases deals with laying the foundation for checking the quality of data, as the use of standards could improve the efficient use of the information system when data quality is addressed. Therefore, applying data quality procedures could help to ensure the quality of data.
Conclusion
To eliminate the challenges with the management of rare diseases, development of an integrated information system considering data architecture is crucial. Identifying data sources, defining datasets and data elements, and defining the interactions between data sources could help to design an integrated rare disease information system that could facilitate information sharing and provide the opportunity for sharing experiences at regional, national, and even transnational levels.
